Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 48

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Targeting Wild-Type and Mutant p53 with Small Molecule CP-31398 Blocks the Growth of Rhabdomyosarcoma by Inducing Reactive Oxygen Species–Dependent Apoptosis

Xu, Jianmin, Timares, Laura, Heilpern, Clay, Weng, Zhiping, Li, Changzhao, Xu, Hui, Pressey, Joseph G., Elmets, Craig A., Kopelovich, Levy, Athar, Mohammad·2010·Cancer Research

Published version of a preprint

Abstract

Rhabdomyosarcoma (RMS) is a common soft-tissue sarcoma of childhood in need of more effective therapeutic options. The expression of p53 in RMS is heterogeneous such that some tumors are wild-type whereas others are p53 mutant. The small molecule CP-31398 modulates both the wild-type and the mutant p53 proteins. Here, we show that CP-31398 blocks the growth of RMS cells that have either wild-type or mutant p53 status. In wild-type A204 cells, CP-31398 increased the expression of p53 and its downstream transcriptional targets, p21 and mdm2; enhanced the expression of apoptosis-related proteins; and reduced proliferation biomarkers. Flow profiling of CP-31398–treated cells indicated an enhancement in sub-G0 and G1 populations. CP-31398 inhibited proliferation in a manner associated with co-induction of SOX9 and p21. Apoptosis induced by CP-31398 occurred with translocation of p53 to mitochondria, leading to altered mitochondrial membrane potential, cytochrome c release, and reactive oxygen species release. In vivo, CP-31398 decreased the growth of tumor xenografts composed of wild-type or mutant p53 tumor cells, increasing tumor-free host survival. Our findings indicate that the ability of CP-31398 to modulate wild-type and mutant p53 results in the inhibition of RMS growth and invasiveness. Cancer Res; 70(16); 6566–76. ©2010 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-10-0942

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 40

  1. Ries, 1999, Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program
  2. Meza, 2006, Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group, J Clin Oncol, 24, 3844, 10.1200/JCO.2005.05.3801 · doi:10.1200/jco.2005.05.3801
  3. Li, 1969, Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome, J Natl Cancer Inst, 43, 1365
  4. Carli, 2004, European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors, J Clin Oncol, 22, 4787, 10.1200/JCO.2004.04.083 · DOI · Paper page
  5. Bassett, 2008, Structural and functional basis for therapeutic modulation of p53 signaling, Clin Cancer Res, 14, 6376, 10.1158/1078-0432.CCR-08-1526 · DOI
  6. Felix, 1992, Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma, Cancer Res, 52, 2243
  7. Hollstein, 1994, Database of p53 gene somatic mutations in human tumors and cell lines, Nucleic Acids Res, 22, 3551
  8. Woods, 2003, Exploiting the p53 pathway for cancer diagnosis and therapy, Hematol J, 4, 233, 10.1038/sj.thj.6200260 · DOI
  9. Foster, 1999, Pharmacological rescue of mutant p53 conformation and function, Science, 286, 2507, 10.1126/science.286.5449.2507 · DOI · Paper page
  10. Tang, 2007, CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice, J Clin Invest, 117, 3753, 10.1172/JCI32481 · DOI · Paper page
  11. Marx, 2007, Oncology. Recruiting the cell's own guardian for cancer therapy, Science, 315, 1211, 10.1126/science.315.5816.1211 · DOI
  12. Rippin, 2002, Characterization of the p53-rescue drug CP-31398 in vitro and in living cells, Oncogene, 21, 2119, 10.1038/sj.onc.1205362 · DOI · Paper page
  13. Wang, 2003, Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding, Mol Cell Biol, 23, 2171, 10.1128/MCB.23.6.2171-2181.2003 · DOI · Paper page
  14. Barlow, 2006, Differentiation of rhabdomyosarcoma cell lines using retinoic acid, Pediatr Blood Cancer, 47, 773, 10.1002/pbc.20650 · DOI
  15. Bache, 1999, G2/M checkpoint is p53-dependent and independent after irradiation in five human sarcoma cell lines, Anticancer Res, 19, 1827
  16. Erster, 2004, In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation, Mol Cell Biol, 24, 6728, 10.1128/MCB.24.15.6728-6741.2004 · DOI · Paper page
  17. Marques-Santos, 2006, Cyclosporin A does not protect the disruption of the inner mitochondrial membrane potential induced by potassium ionophores in intact K562 cells, Cell Biol Int, 30, 197, 10.1016/j.cellbi.2005.10.021 · doi:10.1016/j.cellbi.2005.10.021
  18. Tay, 2005, Mitochondrial permeability transition as a source of superoxide anion induced by the nitroaromatic drug nimesulide in vitro, Free Radic Biol Med, 39, 949, 10.1016/j.freeradbiomed.2005.05.013 · DOI
  19. Smiley, 1991, Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1, Proc Natl Acad Sci U S A, 88, 3671, 10.1073/pnas.88.9.3671 · DOI · Paper page
  20. Di Lisa, 1995, Mitochondrial membrane potential in single living adult rat cardiac myocytes exposed to anoxia or metabolic inhibition, J Physiol, 486, 1, 10.1113/jphysiol.1995.sp020786 · DOI · Paper page
  21. Huang, 2008, Reactive oxygen species mediate oridonin-induced HepG2 apoptosis through p53, MAPK, mitochondrial signaling pathways, J Pharmacol Sci, 107, 370, 10.1254/jphs.08044FP · DOI
  22. Gentile, 2008, The Met tyrosine kinase receptor in development and cancer, Cancer Metastasis Rev, 27, 85, 10.1007/s10555-007-9107-6 · DOI · Paper page
  23. Passeron, 2009, Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid, J Clin Invest, 119, 954
  24. Levine, 1991, The p53 tumour suppressor gene, Nature, 351, 453, 10.1038/351453a0 · DOI · Paper page
  25. Liang, 2009, PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein, Int J Oncol, 35, 1015
  26. Zache, 2008, PRIMA-1(MET) inhibits growth of mouse tumors carrying mutant p53, Cell Oncol, 30, 411
  27. Miyachi, 2009, Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells, Clin Cancer Res, 15, 4077, 10.1158/1078-0432.CCR-08-2955 · DOI
  28. Zhang, 2009, Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-2 interaction, Anticancer Drugs, 20, 416, 10.1097/CAD.0b013e32832aa7b0 · DOI
  29. Coutts, 2009, p53 ubiquitination by Mdm2: a never ending tail?, DNA Repair (Amst), 8, 483, 10.1016/j.dnarep.2009.01.008 · DOI
  30. Tanner, 2004, CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity, J Negat Results Biomed, 3, 5, 10.1186/1477-5751-3-5 · DOI
  31. Bullock, 2001, Rescuing the function of mutant p53, Nat Rev Cancer, 1, 68, 10.1038/35094077 · DOI · Paper page
  32. Taylor, 2000, P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines, Med Pediatr Oncol, 35, 96, 10.1002/1096-911X(200008)35:2<96::AID-MPO2>3.0.CO;2-Z · DOI
  33. Conzen, 2000, Induction of cell cycle progression and acceleration of apoptosis are two separable functions of c-Myc: transrepression correlates with acceleration of apoptosis, Mol Cell Biol, 20, 6008, 10.1128/MCB.20.16.6008-6018.2000 · DOI
  34. Chen, 2000, Role of p53 in cell cycle regulation and apoptosis following exposure to proteasome inhibitors, Cell Growth Differ, 11, 239
  35. Takimoto, 2002, The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein, Cancer Biol Ther, 1, 47, 10.4161/cbt.1.1.41 · DOI
  36. Luu, 2002, The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/mitochondrial/caspase-9 pathway, Exp Cell Res, 276, 214, 10.1006/excr.2002.5526 · DOI
  37. Mihara, 2003, p53 has a direct apoptogenic role at the mitochondria, Mol Cell, 11, 577, 10.1016/S1097-2765(03)00050-9 · DOI · Paper page
  38. Kurrey, 2009, Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells, Stem Cells, 27, 2059, 10.1002/stem.154 · DOI · Paper page
  39. Wang, 2009, p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug, Nat Cell Biol, 11, 694, 10.1038/ncb1875 · DOI · Paper page
  40. Bolos, 2003, The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors, J Cell Sci, 116, 499, 10.1242/jcs.00224 · DOI · Paper page

Cited by

See all 48

Metadata

Authors
Xu, J., Timares, L., Heilpern, C., Weng, Z., Li, C., Xu, H., Pressey, J. G., Elmets, C. A., Kopelovich, L., & Athar, M.
Venue
Cancer Research
Published
2010-08-14
Volume
70
Issue
16
Pages
6566-6576
ISSN
  • 0008-5472
  • 1538-7445
Cited by
48
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting Wild-Type and Mutant p53 with Small Molecule CP-31398 Blocks the Growth of Rhabdomyosarcoma by Inducing Reactive Oxygen Species–Dependent Apoptosis. https://app.cochat.ai/papers/10.1158/0008-5472.can-10-0942
The paper
Xu, J., Timares, L., Heilpern, C., Weng, Z., Li, C., Xu, H., Pressey, J. G., Elmets, C. A., Kopelovich, L., & Athar, M. (2010). Targeting Wild-Type and Mutant p53 with Small Molecule CP-31398 Blocks the Growth of Rhabdomyosarcoma by Inducing Reactive Oxygen Species–Dependent Apoptosis. Cancer Research. https://doi.org/10.1158/0008-5472.can-10-0942

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.